Albeit with the evidence in preclinical studies, there was a paucity of investigations to validate the synergy of denosumab, a potential potent inhibitor of RANKL/RANK, with TKIs and ICIs despite the development of treatment strategies of HCC and BoM. This evidence concerns the gene GRHL2 and hepatocellular carcinoma.